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As the population of older adults in the United States grows, not only will there be an increased 
number of potential older adult organ donors, but the number of older adults with end-stage 
liver disease who need liver transplantation will also increase. As a transplant community, it is 
imperative to know how to utilize these older donors and care for older liver transplant 
recipients.  
 
First, the underutilization of older liver donors (age≥70) represents a possible expansion of the 
donor pool. However, older donor grafts have been historically associated with poor outcomes 
and higher discard rates, but clinical protocols, organ allocation, and the donor pool have 
changed in the last 15 years. Using national registry data from 2003-2016, we estimated the odds 
of discard of older liver donors was two-fold higher every year compared to younger liver 
donors and that discard of older liver donors increased over this time period. Yet, outcomes in 
older liver donor recipients improved over time (40% lower risk of graft loss and 41% lower risk 
of mortality), and these were more marked improvements than seen in younger liver donor 
recipients (Chapter 2). 
 
Secondly, given the increased burden of end-stage liver disease in older adults, we focused on 
temporal trends in the incidence of transplantation and outcomes for older liver transplant 
recipients (Chapter 3). Using national registry data, we found that liver transplantation in older 
recipients increased five-fold from 2003 to 2016 and that length of stay, acute rejection, graft 




Finally, as the average age of waitlisted liver candidates and liver transplant recipients continues 
to increase, we sought to quantify the association of waitlist mortality and frailty, a state of 
decreased physiologic reserve by candidate age. We found that older candidates experienced 
higher rates of frailty than younger candidates. However, regardless of age, frailty was associated 
with nearly two-fold increased risk of waitlist mortality. 
 
Overall, this dissertation quantifies the utilization of older liver donors, outcomes for recipients 
of older liver donors, outcomes of older liver transplant recipients, and delves into the 
relationship between age and frailty in liver transplant candidates.  
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Chapter 1. Introduction 
 
 
Over 14,000 patients are currently on the U.S. liver transplant waitlist, yet only 8,082 liver 
transplants were performed in 2017.2 Each year more than 10% of liver waitlist candidates die 
awaiting transplantation,3 making the donor shortage a significant public health problem.4,5 The 
disparity between the number of available liver donors and the demand of the liver transplant 
waitlist has motivated novel ways to expand the donor pool. Donor characteristics such as 
Hepatitis C virus positive donors, older age, high body mass index, and donation after cardiac 
death are examples of higher risk donors that are used cautiously in the transplant community. 
Specifically, one controversial approach that has been used over the past 3 decades is utilization 
of older liver donors (age≥70).6-8 However, this potential donor pool is becoming increasingly 
more relevant and timely, as nearly 15% of the U.S. population is projected to be older than age 
70 by 2030.9 With continued attention to the use of older liver donor grafts and the donor 
shortage, utilization of older liver donor grafts has likely evolved.  
 
Older liver donor grafts have historically been associated with recipient graft loss and mortality, 
which has led to reluctance to transplant these organs.10-14 For this reason, older liver donor 
grafts only accounted for 4.3% of all liver donors from 2007-201115 with substantial center-level 
variation in older liver donor graft transplantation, ranging from 0-33% of all transplanted 
grafts.16 While several single-center studies reported more routine use of older liver donors and 
showed similar graft and patient survival regardless of donor age, but these studies were limited 
by small sample size.17-20 Yet, older liver donors offer a survival benefit for recipients across all 
model for end-stage live disease scores compared to remaining on the waitlist.21 Furthermore, a 
more up-to-date exploration of national changes in older liver donor grafts is necessary, as 
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temporal changes in older liver donor graft utilization and recipient outcomes have likely 
changed with evolving donor and recipient demographic trends (increasing age of liver 
transplant recipients22 and donors,23,24 indication for liver transplantation22,25), treatment for 
Hepatitis C virus with direct-acting antivirals, and changes in liver allocation policy (e.g. Share 35, 
hepatocellular carcinoma exception points).  
 
As the proportion of older adults in the United States population grows, not only are there more 
potential older organ donors, but the number of older adults with end-stage liver disease is also 
increasing. The burden of end-stage liver disease in older adults (aged ≥65) in the United States 
is increasing,22,26-28 and older adults comprise 23.8% of the current liver transplant waitlist, up 
from 8% in 2002.22,29 The increase in older adults with end-stage liver disease is driven by the 
aging population with hepatitis C virus cirrhosis along with the increase in nonalcoholic 
steatohepatitis and hepatocellular carcinoma, which typically affect older adults.27,28,30,31 
Historically, older adults were denied access to liver transplantation because of poor 
posttransplant survival,32-34 but there are more recent reports of liver transplantation in older 
adults, including small reports of liver transplantation in octogenarians.35,36 
 
It is possible that advances in immunosuppression regimens and surgical techniques 37-40 may be 
leading to improved liver transplant outcomes in older adults. However, older adults are uniquely 
susceptible after liver transplant given increased comorbidity, higher prevalence of frailty, and 
physical impairment.41-43 Among older liver transplant candidates and recipients, physical 
impairment, frailty, and older age are associated with an increased risk of mortality.22,42,44-46 
Additionally, older adults have immunosenescence, leading to lower tolerance of posttransplant 
immunosuppression.47-49 Therefore, improvements in modern immunosuppression may not 
translate to improved posttransplant outcomes over time in older recipients. Further, poor 
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outcomes in older liver transplant recipients are typically due to cardiac complications, 
malignancy, and infection,32,33,50 so surgical and immunosuppression changes do not necessarily 
translate into improved outcomes for older recipients. A better understanding of the trends over 
time in outcomes for older liver transplant recipients is warranted for appropriate referral, 
evaluation, and counseling prior to transplantation.  
 
As a transplant community, we are obligated to identify the best transplant candidates to 
undergo transplantation, not only because of the national organ shortage, but also to do what is 
in the best interest for our patients. Thus, identification of appropriate transplant candidates is 
imperative and improvement of suboptimal transplant candidates in preparation for 
transplantation is important. One way to identify appropriate transplant candidates is through 
frailty assessments. Frailty, a measure of physiologic reserve and increased vulnerability to 
stressors, was initially described by gerontologists in older community dwelling adults.51 Frailty 
was subsequently examined in older general surgery patients,52 kidney transplant candidates and 
recipients,41,49,53-59 and recently in liver transplant candidates and recipients, 44,60-64 where it was 
found to be associated with adverse outcomes in these populations. The Liver Frailty Index, 
comprised solely of performance-based measures (grip strength, balance testing, and chair 
stands), was developed and validated in patients with cirrhosis evaluated for transplantation44,60 
and improves risk prediction for waitlist mortality over the Model for End-Stage Liver Disease 
(c-statistic: 0.80 vs. 0.76). Up to 25% of liver transplant candidates are frail;44,60 beyond waitlist 
mortality,44,65 frailty is associated with increased hospitalizations64 and depression61 in liver 





While there is a higher prevalence of frailty in older adults, there is also a greater burden of 
comorbidities41-43 and an increased prevalence of functional impairment in older adults.42 Older 
candidates may therefore, because of comorbidity burden and underlying functional impairment, 
have a more marked association between frailty and waitlist mortality as compared to younger 
candidates. Yet, studies of frailty in liver transplant candidates have not examined whether there 
is effect modification by candidate age on the association between frailty and waitlist mortality: 
in other words, whether frailty has the same impact on younger patients as it does on older 
patients.44,60 As the average age of waitlisted liver candidates and liver transplant recipients 
continues to increase,22,66 it is even more important to understand this effect.  
 
The population of older adults in the United States has increased substantially within the past 
few decades; however, the impact of age on outcomes for liver transplant recipients of older 
donors and separately on older recipients is not well characterized. This dissertation seeks to 
improve the understanding of liver transplantation with older donors and in older recipients. 
Chapter 2 quantifies the temporal trends in discard and utilization of older liver donor grafts, 
quantifies the organ procurement organization level variation in older liver donor graft discard, 
and characterizes the changing landscape of older liver donor grafts and their recipients. 
Additionally, Chapter 2 describes the trends over the last 15 years in graft loss and mortality for 
older liver donor recipients and compares posttransplant outcomes between recipients of older 
donors and younger donors. Chapter 3 details the temporal trends in liver transplantation and 
posttransplant outcomes, such as length of stay, acute rejection, graft loss, and mortality, for 
older recipients. Chapter 4 describes the prevalence of frailty in older liver transplant candidates 
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Importance: In light of the growing population of older adults in the U.S., older liver donors 
(age≥70) represent an expansion of the donor pool, yet are underutilized. Older liver donor 
grafts were historically associated with poor outcomes and higher discard rates, but clinical 
protocols, organ allocation, and the donor pool have changed in the last 15 years. 
Objective: We sought to evaluate trends in demographics, discard, and outcomes of older liver 
donors (OLDs, age≥70) and OLD recipients in a large national cohort.  
Design: Prospective cohort study between 1/1/2003- 12/31/2016 in the United States.   
Setting: The Scientific Registry of Transplant Recipients includes data on all transplant 
recipients in the United States, submitted by members of the Organ Procurement and 
Transplantation Network. 
Participants: We studied 4,127 older liver donor grafts, 3,350 liver-only older donor recipients, 
78,990 younger liver donors (age 18-69) grafts, and 64,907 liver-only younger donor recipients. 
Exposures: Year of liver transplant and donor age.  
Main outcomes and measures: Graft discard using multilevel logistic models and 
posttransplant outcomes (graft loss, mortality) using Cox proportional hazards models.   
Results: After adjusting for donor characteristics other than age and accounting for OPO-level 
variation, older liver donor grafts were more than 2-times as likely to be discarded compared to 
younger liver donor grafts in each era (2003-2006 aOR: 1.681.972.31, 2007-2009 aOR: 2.172.553.01, 
2010-2013 aOR: 1.682.042.46, and 2013-2016 aOR: 1.962.372.86; all p<0.001). Furthermore, 
transplants with older liver donor grafts represented a progressively lower proportion of all adult 
liver transplants, from 6.0% (n=258) in 2003 to 3.2% (n=211) in 2016 (p=0.001). However, 
outcomes in older liver donor recipients improved dramatically over time, with 40% lower graft 
loss risk (aHR: 0.530.600.68, p<0.001) and 41% lower mortality risk (aHR: 0.520.590.68, p<0.001) in 
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2010-2016 versus 2003-2009; this was well beyond the general temporal improvements in 
younger liver donors recipients (interaction p=0.03 and p=0.04, respectively).  
Conclusions and relevance: Over the past 15 years, graft loss and mortality for older liver 
donor recipients improved dramatically, yet older liver donor graft discard remains more than 
two-fold increased and transplantation with older liver donor grafts decreased. Expansion of the 






Over 14,000 patients are currently on the United States liver transplant (LT) waitlist, yet only 
8,082 LTs were performed in 2017.2 Each year more than 10% of liver waitlist candidates die 
awaiting transplantation,3 making the donor shortage a significant public health problem.4,5 The 
disparity between the number of available liver donors and the demand of the LT waitlist has 
motivated novel ways to expand the donor pool. One controversial approach that has been 
cautiously used over the past 3 decades is utilization of older liver donors (OLDs; age≥70).6-8 
However, this potential donor pool is becoming increasingly more relevant and timely, as nearly 
15% of the U.S. population is projected to be older than age 70 by 2030.9 With continued 
attention to the use of OLD grafts and the donor shortage, utilization of OLD grafts has likely 
evolved. A description of the temporal trends in OLD graft discard and OLD recipient 
outcomes could inform clinical decision-making and expansion of this potential donor pool.  
 
OLD grafts have historically been associated with graft loss and recipient mortality, which has 
led to reluctance to transplant these organs.10-14 For this reason, OLD grafts only accounted for 
4.3% of all liver donors from 2007-201115 with substantial center-level variation in OLD 
transplantation, ranging from 0-33% of all transplanted grafts.16 While several single-center 
studies reported more routine use of OLDs and showed similar graft and patient survival 
regardless of donor age, these studies were limited by small sample size.17-20 Furthermore, a more 
up-to-date exploration of national changes in OLD grafts is necessary, as temporal changes in 
OLD graft utilization and recipient outcomes have likely changed with evolving donor and 
recipient demographic trends (increasing age of LT recipients22 and donors,23,24 indication for 
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LT22,25), treatment for HCV with direct-acting antivirals, and changes in liver allocation policy 
(e.g. Share 35, hepatocellular carcinoma exception points).  
 
To inform clinical practice with OLD grafts, we used national registry data to: 1) quantify trends 
in discard and utilization of OLD grafts, 2) quantify organ procurement organization (OPO) 
level variation in OLD graft discard, 3) characterize the changing landscape of OLD grafts and 
their recipients, and 4) describe trends over the last 15 years in graft loss and mortality for OLD 
recipients. Finally, for context, we compared trends in liver graft discard and posttransplant 




Data source  
This study used data from the Scientific Registry of Transplant Recipients (SRTR) with available 
follow-up through March 2017. The SRTR data system includes data on all donors, waitlisted 
candidates, and transplant recipients in the U.S. submitted by members of the Organ 
Procurement and Transplantation Network (OPTN), and has been described elsewhere.68 
Mortality and graft loss were augmented through linkage with the Social Security Master Death 
File, data from Centers for Medicare and Medicaid Services (CMS), and waitlist data. The Health 
Resources and Services Administration (HRSA), the U.S. Department of Health and Human 
Services, provides oversight to the activities of OPTN and SRTR contractors. This study was 






We identified 4,127 OLD grafts (liver grafts from older liver donors age ≥70) recovered for LT 
and 3,350 deceased liver-only OLD recipients (recipients of LTs from donors age ≥70) between 
January 1, 2003 and December 31, 2016. Also, we identified 78,990 YLD grafts (liver grafts from 
younger liver donors age 18-69) grafts recovered for LT and 64,907 deceased liver-only YLD 
recipients (recipients of LTs from donors age 18-69) in the same time period. We empirically 
grouped recipients into four time strata to reflect changes in allocation policy and general 
evolution of immunosuppression regimens: 2003-2006, 2007-2009, 2010-6/18/2013 and 
6/19/2013-2016. We divided the recent periods at 6/18/2013 to evaluate trends before and 
after implementation of the Share 35 policy change, which increased regional sharing of liver 
allograft offers to patients with Model for End-Stage Liver Disease (MELD) score ≥35. 
Calculated MELD score is laboratory MELD, comprised of sodium, bilirubin, international 
normalized ratio, and creatinine, at time of transplant. Allocation MELD score is reported as the 
allocation score at time of transplant. The MELD score is a measure of disease severity and 
likely survival in patients awaiting liver transplantation. Recipients with missing body mass index 
(BMI; 3.1%) and missing cold ischemia time (3.8%) were excluded from the analysis. 
 
OLD graft discard over time  
We estimated the percentage of liver graft discard (defined as recovered but not transplanted) 
according to donor age in each time stratum. To characterize the change over time in OLD graft 
discard, we ran a multilevel logistic regression model with random intercept with an interaction 
between donor age and time stratum. This model also accounted for underlying variation across 
OPOs. All models were adjusted for donor cause of death, sex, race, donation after cardiac 




OPO-level variation in OLD graft discard 
To characterize the variation in OLD graft discard across OPOs, we ran a multilevel logistic 
regression model with random intercept for OPO among only OLD grafts and calculated each 
OPOs individual rate of OLD graft discard, adjusted for donor race, gender, BMI, HCV, cause 
of death, and DCD. The intraclass correlation coefficient (ICC) from this model quantifies the 
variance in OLD graft discard explained by the OPO where the OLD graft was recovered. We 
calculated the probability that an OLD graft was discarded for each OPO. From this model, we 
derived the national average probability of discard and the probability of discard within the 
highest utilizing OPOs (lowest quartile of OLD graft discard). We then estimated the number of 
OLD grafts that would not have been discarded if all OPOs discarded at or below the national 
average and separately if all OPOs discarded at or below the lowest quartile of OLD graft 
discard. In other words, how many additional OLDs would have been used for transplant if 
OLDs were discarded at rates observed in high utilizing OPOs.  
 
OLD recipients over time  
We calculated the percentage of adult liver transplant recipients who received OLDs annually 
during the study period. Cuzick test of trend was used to compare changes in the number of 
OLD recipients over the study period. We compared the recipient, donor, and transplant 
characteristics of OLD recipients for each time stratum (see “Study Population” above).  
 
Mortality and all-cause graft loss in OLD recipients over time  
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Mortality and all-cause graft loss were estimated at 1-, 3- and 5-years using the Kaplan-Meier 
method for each time stratum. The Kaplan-Meier method was also used to create unadjusted 
cumulative incidence curves of mortality and all-cause graft loss for each time stratum. Cox 
proportional hazards models for mortality and all-cause graft loss were adjusted recipient (sex, 
age, race, BMI, primary diagnosis, MELD, life support at LT, hepatocellular carcinoma [HCC], 
HCV, HIV status, diabetes status, primary insurance, portal vein thrombosis), donor factors 
(race, BMI, HCV, DCD), and transplant factors (cold ischemia time, shared organ status). To 
test whether temporal trends in mortality and graft loss differed between liver donor age groups, 
interactions between donor age (OLD and YLD) and each outcome were explored. For all 
models, proportional hazards assumptions were assessed with visual inspection of 
complementary log-log plots and Schoenfeld residuals. 
 
Statistical analyses  
Continuous variables were compared using t-tests and categorical variables were compared using 
χ2 tests. Race was reported by clinicians to the OPTN. Confidence intervals are reported as per 
the method of Louis and Zeger.70 All analyses were two-tailed and α was set at 0.05. All analyses 




Study population: OLDs 
We identified 4,127 OLD grafts (liver grafts from OLDs) recovered for LT. Among OLD grafts 
recovered across the entire study period (between 2003-2016), 54% were aged 70-74, 33% were 
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75-79, 11% were 80-84, and 2% were ≥85 (Table 1A). Among 747 discarded OLD grafts, 51% 
of OLDs were aged 70-74, 33% of OLDs were 75-79, 13% of OLDs were 80-84, and 3% of 
OLDs were ≥85 (Table 1B). Among 3,350 utilized OLDs for liver-only OLD recipients, 55% of 
OLDs were aged 70-74, 33% of OLDs were 75-79, 10% of OLDs were 80-84, and 2% of OLDs 
were ≥85.  
 
Changing landscape of recovered and discarded OLD characteristics  
The average donor BMI of recovered OLD grafts increased from 26.1 in 2003-2006 to 28.0 in 
2013-2016 (p<0.001). Recent OLDs were less likely to be Caucasian (69.9% in 2013-2016 vs. 
80.6% in 2003-2006, p<0.001) and less likely to be DCD grafts (0.1% in 2013-2016 vs. 0.7% in 
2003-2006, p=0.008) (Table 1A). Similarly, the average BMI of discarded OLDs increased from 
26.7 in 2003-2006 to 28.7 in 2013-2016 (p=0.008). Recently discarded OLD grafts were less 
likely to be from Caucasian OLDs (73.7% in 2013-2016 vs. 80.8% in 2003-2006, p=0.03)(Table 
1B). 
 
OLD graft discard over time  
OLD graft discard increased from 11.6% in 2003, to a peak of 24.5% in 2008, and down to (but 
still higher than 2003) 15.4% in 2016; OLD graft discard was higher every year in the study 
period compared to YLD graft discard (2003: 11.6% vs. 8.0%, 2008: 24.5% vs. 13.1%, 2016: 
15.4% vs. 9.3%) (Figure 1A).  After adjustment, OLD grafts were more than twice as likely to be 
discarded compared to YLD grafts in each era (2003-2006 aOR:1.681.972.31, 2007-2009 aOR: 




OPO-level variation in OLD and YLD graft discard 
Among the 58 OPOs in the United States, OLD graft discard ranged widely from 0-35.3% with 
a median OLD graft discard of 15.1% (IQR:9.8-25.0%). The ICC was 0.057, meaning that only 
5.7% of the variation in OLD graft discard was explained by OPO (Figure 1B). The OPO-
specific odds ratios of OLD discard ranged from 0.31 (95%CI:0.17-0.58) to 2.69 (2.20-3.29) 
compared to the national odds of OLD discard (OR=1). Four (6.9%) of 58 OPOs had a 
statistically significantly higher odds ratio and four had statistically significantly lower odds ratio 
of OLD discard as compared to the national average (Figure 1B). If all OPOs discarded OLD 
grafts at or below the 25th percentile of discard, 277 more OLD grafts would have been used: a 
34% reduction in OLD graft discard. If all OPOs discarded at or below the national average, 177 
more OLD grafts have been used: a 24% reduction in OLD graft discard. 
 
Among the 58 OPOs in the United States, YLD graft discard ranged from 3.2-20.7% a median 
YLD graft discard of  9.3% (IQR:7.3-12.4%). The ICC was 0.096, meaning that only 9.6% of the 
variation in YLD discard was attributed to the OPO level. The OPO-specific odds ratios of 
YLD discard ranged from 0.23 (95%CI: 0.17-0.33) to 2.23 (95%CI: 1.70-2.93) compared to the 
national odds of YLD discard (OR=1). Six (10.3%) of 58 OPOs had a statistically significantly 
higher odds ratio and twenty-seven (46.6%) had statistically significantly lower odds ratio of 
younger liver donor discard as compared to the national average (Figure 1C).   
 
Study population: OLD recipients 
The average age of 3,350 OLD recipients (recipients of OLD grafts) was 57.6 years, 37.6% were 
female, and 73.8% were Caucasian (Table 2). The average calculated MELD score at time of LT 
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for OLD recipients was 19 (SD=8). The indications for LT were alcoholic cirrhosis (21.2%), 
HCV (13.7%), HCC (18.6%), nonalcoholic steatohepatitis (10.0%), primary biliary cirrhosis 
(5.0%), and primary sclerosing cholangitis (5.0%).  
 
Changing landscape of OLD recipients   
The number of OLD recipients steadily declined from 258 in 2003 to 211 in 2016 (Figure 2); the 
percentage of OLD recipients among all adult liver recipients also decreased from 6.0% to 3.2% 
(p=0.001). The average age of OLD recipients increased from 55.9 years in 2003 to 59.8 years in 
2016 (p<0.001). Among recipients of OLD grafts, the percent of older (age≥65) OLD graft 
recipients increased over the study period from 2003 to 2016 from 9.3% to 20.2%. Among OLD 
recipients from 2013-2016 versus 2003-2006, sex (female: 38.4% vs. 37.9%, p=0.94), BMI (28.1 
vs. 28.2 kg/m2, p=0.07), and race (Caucasian: 73.0% vs. 74.6%, p=0.26) did not differ 
significantly. Additionally, the average calculated MELD score for OLD recipients at time of LT 
did not change (18 vs. 18, p=0.80), but the average allocation MELD score increased (25 vs. 21, 
p<0.001). Recent OLD recipients were more likely to have non-alcoholic steatohepatitis (16.9% 
in 2013-2016 vs. 4.1% in 2003-2006) or HCC (22.6% vs. 10.6%) and less likely to have HCV 
(11.5% vs. 20.0%) as the primary indication for LT (p<0.001) (Table 2).  
 
Recently transplanted OLDs were more likely have higher BMI (27.8 vs. 25.9 kg/m2, p<0.001). 
Also, recently transplanted OLDs were more likely to have anoxia (13.5% vs. 5.1%, p<0.001) 
and head trauma (17.1% vs. 12.5%, p<0.001) as the cause of death (Table 2).  
 
Mortality in OLD recipients over time  
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Mortality in both OLD and YLD recipients improved over time (Figures 3A, 3C). In OLD 
recipients from 2003-2009 to 2010-2016, 1-year mortality improved from 18% to 11%, 3-year 
from 28% to 18%, and 5-year from 37% to 23%. In YLD recipients, from 2003-2009 to 2010-
2016, 1-year mortality improved from 13% to 11%, 3-year from 22% to 14%, and 5-year from 
28% to 21%. The improvements in mortality over time were greater in OLD recipients 
(interaction p=0.04)(Figure 3C): OLD recipients from 2010-2016 were at a 41% lower risk of 
mortality compared to OLD recipients from 2003-2009 (aHR: 0.520.590.68, p<0.001), and YLD 
recipients from 2010-2016 were at a 31% lower risk of mortality compared to 2003-2009 (aHR: 
0.660.690.71,p<0.001).  
 
All-cause graft loss in OLD recipients over time  
Like mortality, graft loss in OLD and YLD recipients improved over time (Figures 3B, 3D). In 
OLD recipients from 2003-2009 to 2010-2016, 1-year graft loss improved from 23% to 15%, 3-
year from 34% to 22%, and 5-year from 43% to 27%. In YLD recipients from 2003-2009 to 
2010-2016, 1-year graft loss improved from 16% to 11%, 3-year from 26% to 19%, and 5-year 
from 32% to 24%. The improvements in graft loss over time were more marked in OLD 
recipients (interaction p=0.03; Figure 3D): OLD recipients from 2010-2016 were at a 40% lower 
risk of graft loss compared to OLD recipients from 2003-2009 (aHR: 0.53 0.600.68, p<0.001) and 
YLD recipients from 2010-2016 were at a 30% lower risk of mortality compared to 2003-2009 






In this national study of 4,427 recovered OLD grafts and 3,350 OLD recipients between 2003-
2016, we observed decreasing utilization of OLD grafts with concomitant significant 
improvements in graft loss and mortality for recipients of these organs. OLD graft discard 
increased from 11.6% to 15.4% over the study period, and the proportion of OLD transplants 
performed among all LTs decreased from 6.0% to 3.2% (p=0.001). However, during the same 
time period, graft loss and mortality dropped by more than half (aHR: 0.47 and 0.44, both 
p<0.001), and improvements in graft loss and mortality for OLD recipients over time were 
significantly higher than improvements seen in YLD recipients.  
 
Our findings of increased OLD graft discard from 2003-2016 are consistent with findings from 
Orman et al. of increased discard of all adult liver donors grafts from 2003-201024 along with 
worsening donor quality over time due to donor obesity, donor diabetes, and DCDs.71 Our 
findings of high OLD graft discard and wide OPO-level variation of OLD graft utilization are 
consistent with previous studies that examined variation in OLD and DCD graft use at the OPO 
level (0-35.3% of adult donor LTs performed)16 and OLD grafts used by UNOS region (0.9-
12.9% of adult donor LTs performed).72 However, we expand on these findings and show that, 
after accounting for other donor characteristics, only 5.7% of the variation in OLD graft discard 
can be explained by OPO. Further, we found that if all OPOs performed at least at the national 
average for OPO discard, 177 more OLD grafts would have been available for LT.  
 
Our findings of improved posttransplant mortality and graft loss over time may be due to several 
factors including patient care, surgical technique, or improved donor: recipient matching. We 
previously identified a recipient phenotype, a preferred recipient, who does not incur additional risk 
associated with OLD graft use.73 Preferred recipients are first-time transplant recipients over the age 
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of 45 with BMI<35, non-status 1 registration, CIT<8 hours, and an indication for liver 
transplantation other than HCV. We recently validated this preferred recipient phenotype and found 
that 28.4% of OLD grafts went to preferred recipients in 2006, but this increased to 59.1% in 
2013, meaning that indeed OLD grafts are more frequently being transplanted in recipients who 
do not incur additional risk of graft loss or mortality with OLD grafts.74 These preferred recipients 
represent a potential group of recipients that could be used for broader utilization of OLD 
grafts. Exclusion of a potential organ donor should not be based on age alone, but donor age 
should be evaluated with donor:recipient matching and consideration of potential cold ischemia 
time. 
 
Strengths of this study include a large, national cohort of OLD grafts and OLD recipients dating 
back to the implementation of the MELD allocation system. However, one notable limitation is 
the inability to determine if the improvement in outcomes was due to improved posttransplant 
care or improved OLD graft candidate selection.73,74 Judicious recipient selection to potentially 
increase OLD graft utilization is imperative; we do not advocate that every candidate receive an 
OLD graft. While the overall improvement in outcomes for OLD recipients is encouraging, 
further study is needed to determine the etiologies of this improvement. Additionally, we cannot 
quantify the potential expansion of the donor pools with increased OLD utilization because 
most potential OLDs were not evaluated by the organ procurement organizations, and discard 
rates are likely underestimated.  
 
In conclusion, there is a continued decline in OLD graft utilization despite improving outcomes 
for OLD recipients over time. Though outcomes for all LT recipients have improved over time, 
there has been a more marked improvement in OLD recipients. These trends may suggest the 
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transplant community has improved selection of who should receive OLD grafts and care for 
OLD recipients, and there may be room for more liberal and broader utilization of OLDs to 
expand the donor pool. These findings can guide OPO evaluation of potential donors, 




Table 1. Characteristics of 4,127 recovered older liver donor (OLD) grafts and 747 discarded 
OLD grafts from 2003-2016.  
Recovered OLD 
grafts  
2003-2006 2007-2010 2011-6/2013 7/2013-2016 p value  
N 1,379 987 856 905   
Donor age, years+  75.1 ±4.0 75.1 ±4.2 74.7 ±3.9 74.3 ±3.6 0.002 
Female, % 55 53.6 55.5 53.7 0.82 
Donor BMI, kg/m2 + 26.1 ±5.0 26.7 ±5.4 27.8 ±5.6 28.0 ±5.9 <0.001 
Race, % 
    
<0.001 
     Caucasian   80.6 77.4 80.4 69.9 
 
     African American  9.9 11.4 12.3 15.5 
 
     Hispanic  6.9 7.8 4.3 10.3 
 
     Asian  2.1 2.9 2.9 4.3  
Hepatitis C, % 0.4 0 0.5 0.4 0.23 
Cause of death, %  
   
<0.001 
     Anoxia  5.7 7.5 10.4 13.9 
 
     Head trauma  12.4 14 13.8 16.6 
 
     Cerebrovascular               
accident 
80.6 77.3 75 68.2 
 
Donation after cardiac 
death, %  
0.7 0.1 0 0.1 0.008 
Discarded OLD 
grafts  
2003-2006 2007-2010 2011-6/2013 7/2013-2016 p value  
N 219 220 156 152   
Donor age, years+  75.6 ±4.1 75.7 ±4.6 75.2 ±3.8 74.3 ±3.9 0.004 
Female, % 53.9 52.3 57.1 55.3 0.82 
Donor BMI, kg/m2 + 26.7 ±5.3 27.8 ±6.2 28.0 ±5.9 28.7 ±6.3  0.008 
Race, % 
    
0.03 
     Caucasian  80.8 77.7 83.7 73.7 
 
     African American  8.7 13.2 8.3 7.9 
 
     Hispanic  7.8 5.9 4.5 10.5 
 
     Asian  1.8 2.3 4.5 7.8  
Hepatitis C, % 0 0 1.3 0.7 0.17 
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Cause of death, %  
   
0.54 
     Anoxia  9.1 10 14.1 15.8 
 
     Head trauma  11.9 10.9 11.5 13.8 
 
    Cerebrovascular 
accident 
78.1 78.2 73.1 68.4 
 
Donation after cardiac 
death, %  
1.4 0.5 0 0.7 0.42 
+mean ± standard deviation  




Table 2. Characteristics of older liver donor (OLD) recipients from 2003-2016.  
 
2003-2006 2007-2010 2011-6/2013 7/2013-2016 p value 
N 1,147 758 698 747 
 
OLD recipient characteristic       
Age, years+  55.9 ±9.7 57.6 ±9.5 58.2 ±9.3 59.8 ±8.5 < 0.001 
Female, % 37.9 37.2 37.3 38.4 0.94 
BMI, kg/m2 + 28.2 ±7.4 28.2 ±6.1 28.3 ±5.8 28.1 ±5.4 0.07 
Race, % 
    
0.26 
     Caucasian  74.6 73.7 73.6 73.0 
 
     African American  6.3 6.5 6.0 5.4 
 
     Hispanic  14.2 12.3 12.4 13.6 
 
     Asian  3.9 6.4 7.2 6.8 
 
Indication for liver transplant, % 
    
<0.001 
     Hepatitis C virus  20.0 10.3 9.6 11.5 
 
     Alcoholic cirrhosis  21.2 21.6 21.4 20.9 
 
     Non-alcoholic steatohepatitis 4.1 10 12.9 16.9 
 
     Hepatocellular carcinoma 10.6 23.2 22.1 22.6 
 
     Primary biliary cirrhosis  4.9 5.1 5.6 4.1 
 
     Primary sclerosing cholangitis   4.7 5.2 5.6 4.8 
 
Calculated MELD score+ 18 ±8 18 ±8 18 ±9 18 ±8 0.80 
Allocation MELD score+ 21 ±7 22 ±6 24 ±7 25 ±6 <0.001 
Status 1/1A, % 4.4 3.9 2.2 0.9 <0.001 
ICU prior to LT, % 11.4 8.2 7.1 6.2 0.001 
Previous transplant, % 3.5 2.4 1.6 1.5 0.02 
Portal vein thrombosis, % 2.2 2.2 3.6 6.4 <0.001 
Diabetes mellitus, % 26.2 30.4 33.2 32.9 <0.001 
Transplant characteristic 
     
Cold ischemia time, hours+  7.7 ±3.5 7.2 ±2.9 6.3 ±2.6 5.7 ±1.9 <0.001 
Shared, % 47.4 45.9 38.7 39.0 <0.001 
+mean ± standard deviation  
















Figure 1. (a) Percent of discarded older liver donor (OLD) and younger liver donor 1 grafts by 
year of liver graft recovered. OLD grafts were more than 2-times as likely to be discarded 
compared to YLD grafts in each era (2003-2006 aOR: 1.68 1.972.31, 2007-2009 aOR: 2.17 2.55 3.01, 
2010-2013 aOR: 1.68 2.042.46, and 2013-2016 aOR: 1.96 2.372.86; all p<0.001) after adjusting for sex, 
race, BMI, cause of death, DCD, and HCV status and accounting for OPO level variation. 
(b) Relative odds of OLD graft discard by organ procurement organization (OPO) compared to 
national average (horizontal line). Each dot represents the relative risk of OLD graft discard for 
each OPO in the United States with 95% confidence interval.  
(c) Relative odds of YLD graft discard by OPO compared to national average (horizontal line). 
Each dot represents the relative risk of YLD graft discard for each OPO in the United States 






Figure 2. Trends in utilization of older liver donor (OLD) grafts according to year of liver 
transplant in OLD recipients. The number of transplanted OLD recipients is shown as a bar (left 

















Figure 3. Cumulative incidence of mortality (a) and all-cause graft loss (b) in older liver donor 
(OLD) recipients. The year and number of liver transplant (LT) recipients is seen to the right of 
the curve. Cumulative incidence of mortality (c) and all-cause graft loss (d) in older liver donor 
(OLD) and younger liver donor 1 recipients. The most recent time periods were split at 
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Background: The burden of end-stage liver disease in older adults has increased; understanding 
trends in liver transplantation (LT) and outcomes for older recipients is imperative for 
evaluation, counseling, and appropriate referral of this vulnerable group of older adults.  
 
Study design and setting: We studied 8,627 older (age≥65) deceased donor liver-only 
transplant recipients using data from the Scientific Registry of Transplant Recipients (1/1/2003-
12/31/2016). We evaluated temporal changes in recipient, donor, and transplant characteristics. 
We also evaluated post-LT length of stay (LOS), acute rejection, graft loss, and mortality using 
logistic regression and Cox proportional hazards.  
 
Results: LT in older adults increased almost 5-fold from 263 in 2003 (9.5% of total LT that 
year) to 1,144 in 2016 (20.7% of total LT). Recent recipients were more likely to be female, 
African American, and have a higher BMI and MELD score. Hepatitis C, non-alcoholic 
steatohepatitis, and hepatocellular carcinoma were the most common indications for LT in 
recent recipients. Comparing those in 2013-2016 to those in 2003-2006, odds of LOS>2 weeks 
decreased 34% (adjusted odds ratio [aOR]:0.66, 95%CI:0.57-0.76, P<.001), 1-year acute rejection 
decreased 30% (aOR:0.70, 95%CI:0.56-0.88, P=.002), all-cause graft loss decreased 54% 
(adjusted hazard ratio [aHR]:0.46, 95%CI:0.40-0.52, P<.001), and mortality decreased 57% 
(aHR:0.43, 95%CI:0.38-0.49, P<.001).  
 
Conclusion: Despite the substantial increase in number and severity of older adults undergoing 
LT, LOS, rejection, graft loss, and mortality have significantly decreased over time. These trends 





The burden of end-stage liver disease (ESLD) in older adults (aged ≥65) in the United States 
(US) is increasing,22,26-28 and older adults comprise 23.8% of the current liver transplant (LT) 
waitlist, up from 8% in 2002.22,29 The increase in older adults with ESLD disease is driven by the 
aging population with hepatitis C virus cirrhosis along with the increase in nonalcoholic 
steatohepatitis and hepatocellular carcinoma, which typically affect older adults.27,28,30,31 
Historically, older adults were denied access to LT because of poor posttransplant survival,32-34 
but there are more recent reports of LT in older adults, including small reports of LT even in 
octogenarians.35,36 
 
It is possible that advances in immunosuppression regimens and surgical techniques 37-40 may be 
leading to improved LT outcomes in older adults. However, older adults are uniquely susceptible 
after LT given increased comorbidity, higher prevalence of frailty, and physical impairment.41-43 
Among older LT candidates and recipients, physical impairment, frailty, and older age are 
associated with an increased risk of mortality.22,42,44-46 Additionally, older adults have 
immunosenescence, leading to lower tolerance of post-LT immunosuppression. 47-49 Therefore, 
improvements in modern immunosuppression may not translate to improved posttransplant 
outcomes over time in older recipients. Further, poor outcomes in older LT recipients are 
typically due to cardiac complications, malignancy, and infection,32,33,50 so surgical and 
immunosuppression changes do not necessarily translate into improved outcomes for older 
recipients. A better understanding of the trends over time in outcomes for older LT recipients is 
warranted for appropriate LT referral, evaluation, and counseling prior to transplantation.  
 
In light of the aging ESLD population, we sought to evaluate and understand the temporal 
trends in LT and post-LT outcomes for older recipients. To inform clinical practice, we used 
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national registry data to: 1) characterize the changing landscape of LT in older adults, and 2) 
describe the trends over the last 15 years in LT length of stay, acute rejection, graft loss, and 




Data source  
This study used data from the Scientific Registry of Transplant Recipients (SRTR) external 
release made available in March 2017. The SRTR data system includes data on all donors, 
waitlisted candidates, and transplant recipients in the United States submitted by members of the 
Organ Procurement and Transplantation Network (OPTN), and has been described elsewhere.68 
All-cause graft loss and mortality were augmented through linkage with the Social Security 
Master Death File, data from Centers for Medicare and Medicaid Services (CMS), and waitlist 
data. The Health Resources and Services Administration (HRSA), the United States Department 
of Health and Human Services, provides oversight to the activities of OPTN and SRTR 
contractors.  
 
Study Population  
We identified 8627 older (age ≥65) deceased donor liver-only transplant recipients between 
January 1, 2003 and December 31, 2016 using data from SRTR. We grouped these recipients by 
year of LT into four strata for empirical reasons and to reflect changes in allocation policy and 
general evolution of immunosuppression regimens: 2003-2006, 2007-2009, 2010-6/18/2013 and 
6/19/2013-2016. We divided the recent time periods at 6/18/2013 to evaluate trends before and 
after implementation of the Share 35 policy change, which increased regional liver allograft 
offers to patients with MELD score ≥35. The annual number and percent of liver transplants 
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for older recipients was examined over time. Donor, recipient, and transplant characteristics 
were examined using t tests for continuous variables and χ2 tests for categorical variables.  
 
Outcomes 
LOS was defined as the duration of hospitalization during the initial transplant episode and 
analyzed as a binary variable ≤2 weeks or >2 weeks using adjusted multiple logistic regression; a 
cut-off previously used in abdominal solid organ transplantation.54,75 Acute rejection within the 
first year of LT was analyzed as a binary variable using adjusted multiple logistic regression. All-
cause graft loss and mortality were estimated at 1-, 3- and 5-years using the Kaplan-Meier 
method for each time stratum.  Kaplan-Meier methods were also used to create unadjusted 
cumulative incidence curves of all-cause graft loss and mortality. Cox proportional hazards 
models for all-cause graft loss and mortality were used to adjust for changes in recipient, donor, 
and transplant characteristics. Proportional hazards assumptions were confirmed with visual 
inspection of complementary log-log plots and Schoenfeld residuals.  
 
Statistical Analyses  
To ensure proper risk adjustment, we adjusted each of the regression models for standard 
factors accounted for in the SRTR program specific reports. This included recipient factors—
sex, age, race, body mass index 67, primary diagnosis, life support, hepatocellular carcinoma, non-
hepatocellular carcinoma malignancy, hepatitis C virus, HIV status, diabetic, primary insurance, 
portal vein thrombosis, and split LT)—and donor factors—age, race, BMI, hepatitis C virus, 
donation after cardiac death, ABO compatibility, cold ischemia time. All analyses were two-tailed 








Among 58,598 adult LT recipients, 8627 (14.7%) were older LT recipients between 2003-2016; 
78% were aged 65-69, 20.1% were aged 70-74, 1.6% were aged 75-79, and 0.1% were aged ≥80. 
Also, 36.1% were female, and 6.4% were African-American (Table 1).   
 
Increase in LT in Older Adults  
The annual number of LTs performed in older adults increased substantially throughout the 
study period (Figure 1A). In 2016, 1144 older adults received LTs (20.7% of all LT recipients), 
up from 263 older LT recipients in 2003 (9.5% of all LT recipients).  
 
Changing Landscape of LT in Older Adults  
LT recipients shifted toward older ages over time (Figure 1B). Older LT recipients became more 
likely to be male (66.0% in 2013-2016 vs 61.1% in 2003-2006, P =.006), African American (7.8 
% vs 3.9%, P <.001), have MELD ≥30 (34.2% vs 13.0%, P <.001), have portal vein thrombosis 
(14.6% vs 5.0%, P <.001), and have non-alcoholic steatohepatitis (19.5% vs 5.8%) or 
hepatocellular carcinoma (28.9% vs 18.4%) as their indication for LT (Table 1). In addition, 
older LT recipients became more likely to receive a hepatitis C virus positive donor (5.3% vs 
1.2%, p<0.001) or DCD donor (7.2% vs 4.8%, P=.003), and became less likely to receive a 
nationally shared donor (4.1% vs 10.6%, P <.001) (Table 1).  
 
Length of Stay over Time  
Median (interquartile range) LOS decreased from 10 (7-18) days in 2003-2006 to 9 (6-16) days in 
2013-2016. LOS >2 weeks for older LT recipients decreased from 30.8% in 2003-2006 to 28.0% 
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in 2013-2016. After adjusting for donor, recipient, and transplant factors, the odds for LOS >2 
weeks in 2013-2016 was 34% lower than in 2003-2006 (adjusted odds ratio [aOR]:0.66, 95% 
CI:0.57-0.76, P <.001) (Table 3).  
 
Acute Rejection over Time  
One-year acute rejection decreased from 14.8% in 2003-2006 to 9.7% in 2013-2016. After 
adjusting for donor, recipient, and transplant factors, one-year acute rejection in 2013-2016 was 
30% lower than in 2003-2006 (aOR:0.70, 95% CI:0.56-0.88, P =.002) (Table 3).  
 
All-Cause Graft Loss over Time  
Graft survival in older LT recipients also improved over time (Figure 2A). One-year survival 
improved from 80% in 2003-2006 to 90% in 2013-2016; 3-year survival improved from 71% to 
84%, and 5-year from 63% to 70% (Table 2). After adjusting for donor, recipient, and transplant 
factors, graft failure in 2013-2016 was 54% lower than it was in 2003-2006 (adjusted hazard ratio 
[aHR]:0.46, 95% CI:0.40-0.52, P <.001) (Table 3).  
 
Mortality over Time  
Patient survival in older LT recipients improved steadily over time (Figure 2B). One-year survival 
improved from 82% in 2003-2006 to 91% in; 3-year survival improved from 73% to 86%, and 5-
year from 65% to 72% (Table 2). After adjusting for donor, recipient, and transplant factors, 
mortality in 2013-2016 was 57% lower than it was in 2003-2006 (aHR:0.43, 95% CI:0.38-0.49, P 






In this national study of 8627 older LT recipients between 2003-2016, we have identified a 
changing landscape in transplantation for older adults, with a dramatic increase in number of 
LTs performed and a significant improvements in LOS, acute rejection, graft survival, and 
patient survival.  There was almost a five-fold increase in the number of older adults who 
underwent LT from 2003 (N=263) to 2016 (N=1144), and older adults accounted for 20.7% of 
total LT recipients in 2016. Older LT recipients were more likely to be male, African American, 
have higher a MELD score and portal vein thrombosis in 2013-2016 as compared to 2003-2006. 
Also, recent older recipients were more likely to undergo LT for hepatitis C virus, non-alcoholic 
steatohepatitis, or hepatocellular carcinoma, and more likely to receive a hepatitis C virus 
positive or donation after cardiac death graft compared to older LT recipients in 2003-2006. 
Despite an increase in the severity of liver disease and number of LTs performed in older 
recipients, from 2003 to 2016 there were significant improvements in acute rejection (aOR: 0.70, 
P=.002) and shorter LOS (aOR: 0.66, P<.001) along with graft loss and mortality (aHR: 0.46 and 
0.43, both P<.001).  
 
Our findings of a significant increase in the number of older adults undergoing LT are consistent 
with reports of increasing numbers of older adults undergoing kidney, heart, and lung 
transplantation.76,77 These studies described a substantial rise in the number and proportion of 
older adults undergoing transplantation, with up to 18.4% of kidney transplant recipients over 
the age of 65.76 Our findings are also consistent with a report of increased LT in recipients over 
the age of 60 by Su et al; we extended their study by evaluating the trends over time in the 
characteristics and outcomes of older LT recipients and found that, despite the changing 
demographics, outcomes have dramatically improved.22 Also, the temporal improvement we 
observed in graft and patient survival for older LT recipients is consistent with improvement in 
graft and patient survival for older KT recipients,76 supporting our hypothesis that 
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improvements in immunosuppression might play a role. Finally, we show a dramatic 
improvement in long-term outcomes for older LT recipients that is different from a recent paper 
that showed no improvement in long-term outcomes for LT recipients of all ages.78 However, 
this report did not stratify outcomes by age, but the majority of LT recipients are under age 65, 
so it seems to be driven by younger patients.  
 
The strengths of this study include a large, unbiased, national cohort of LT recipients (i.e. every 
recipient in the United States) dating back to the implementation of the MELD allocation 
system. While we are limited by the general coarseness of comorbidity data in the national 
registry, it is unlikely that differences in comorbidities would explain the dramatically observed 
improvement in outcomes seen in recent years, especially given that older LT recipients are now 
sicker than those in the past (so any potential bias would be toward the null).  
 
LT in older recipients increased dramatically in the last 15 years, with improvements in length of 
stay, acute rejection, graft survival, and patient survival in these recipients. Older patients with 
ESLD and their providers should be aware of these findings, and increased age per se should not 
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  Age (years), mean± SD 68.0± 2.7 67.8± 2.6 67.8± 2.5 67.6± 2.4 .001 
  Female, % 38.9 37.2 36.9 34.0 .006 
  BMI, mean± SD 27.4± 4.9 27.9± 5.3 28.0± 5.1 28.4± 5.1 <.001 
  Race, % 
 
   
 
       White  77.7 74.1 73.8 73.8 <.001 
       African American  3.9 5.1 6.7 7.8  
  Indication for LT, % 
 
   
 
       HCV cirrhosis 16.5 12.6 15.8 18.1 <.001 
       Alcoholic cirrhosis  12.6 14.1 12.7 13.0  
       NASH 5.8 13.0 14.2 19.5  
       HCC 18.4 27.9 29.1 28.9  
       Cholestatic liver 
disease 
10.0 8.3 7.8 6.7  
       Non-cholestatic 
cirrhosis  
26.4 18.2 13.8 8.6  
  MELD, % 
 
   
 
       <10 3.0 1.4 0.6 0.4 <.001 
       10-19  28.3 20.7 12.7 11.4 
 
       20-29 53.8 62.7 58.3 52.9  
       30-39 11.1 10.6 20.2 27.5  
       ≥40 1.9 3.6 6.4 6.7  
       Status 1/1A 1.9 1.1 1.7 1.2  
  Life support (prior to 
LT) 
2.8 3.1 4.7 5.3 <.001 
  Ascites, % 2.0 2.0 2.0 1.9 .001 
  Albumin (g/dL) 1.1 1.1 1.1 1.2 <.001 
  Portal vein thrombosis, 
% 
5.0 8.9 14.3 14.6 <.001 
  Comorbidities, % 
 
       HIV  0.1 0.1 0.1 0.2 .79 
       HCV  27.5 27.6 30.2 32.6 <.001 




  Cold ischemia time 
(hours), % 
 
   
 
         0-8  72.3 80.6 88.4 88.5 <.001 
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         9-11 18.0 14.2 9.8 9.7  
         ≥12  9.7 5.2 1.8 1.8  
  ABO incompatible, %  0.5 0.5 0.7 1.0 .08 
  Split graft, % 1.2 1.9 1.7 1.5 .37 
Donor characteristic 
 
  Age, % 
 
   <.001 
       <18  6.2 6.2 5.1 5.1  
       18-39 28.8 32.8 34.6 36.5  
       40-49 18.7 17.5 16.9 17.1  
       50-59 19.0 18.3 20.2 20.3  
       60-69 15.4 13.8 15.0 14.3  
       ≥70 12.0 11.5 8.2 6.7  
  Female, % 44.9 40.2 43.1 40.8 .02 
  Race, %  
       White  71.6 64.4 66.0 65.7 <.001 
       African American  14.3 17.2 19.4 18.8  
DCD, % 4.8 6.4 5.4 7.2 .003 
HCV, % 1.2 1.8 2.3 5.3 <.001 
 
HCV= hepatitis C virus, NASH= nonalcoholic steatohepatitis, HCC= hepatocellular carcinoma, 
DCD= donation after cardiac death  
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Table 2. Patient and all-cause graft survival at 1-, 3-, and 5-year in older recipients according to 
year of liver transplantation (LT).  
 
Year of LT  Older recipients (N= 8,627) 
  N % 
1-year 3-year 5-year 
Graft survival      
2003-2006  1453 80 71 63 
2007-2009 1544 85 74 67 
2010-06/18/2013 2222 85 76 70 
06/19/2013-2016 3408 90 84 -- 
Patient survival      
2003-2006  1453 82 73 65 
2007-2009 1544 87 76 69 
2010-06/18/2013 2222 86 78 72 
06/19/2013-2016 3408 91 86 -- 
 
*The two latest time periods were split at 6/18/2103 after the allocation policy implementation 




Table 3. Length of stay, one-year acute rejection, all-cause graft loss, and mortality for older liver 
transplant (LT) recipients.  
   
Year of LT  Older recipients (N= 8,627) 
Length of stay >2 
weeks 
N aOR (95% CI) P value 
2003-2006  1453 Reference 
2007-2009 1544 0.83 (0.71, 0.98) P=.03 
2010-06/18/2013 2222 0.73 (0.63, 0.85) P<.001 
06/19/2013-2016 3408 0.66 (0.57, 0.76) P<.001 
One-year acute 
rejection  
N aOR (95% CI) P value 
2003-2006  1453 Reference 
2007-2009 1544 1.00 (0.79, 1.27) P=.99 
2010-06/18/2013 2222 0.74 (0.58, 0.93) P=.01 
06/19/2013-2016 3408 0.70 (0.56, 0.88) P=.002 
All-cause graft loss  N aHR (95% CI) P value 
2003-2006  1453 Reference 
2007-2009 1544 0.83 (0.75, 0.92) P=.001 
2010-06/18/2013 2222 0.68 (0.61, 0.75) P<.001 
06/19/2013-2016 3408 0.46 (0.40, 0.52) P<.001 
Mortality  N aHR (95% CI) P value 
2003-2006  1453 Reference 
2007-2009 1544 0.83 (0.75, 0.93) P=0.001 
2010-06/18/2013 2222 0.67 (0.60, 0.75) P<.001 
06/19/2013-2016 3408 0.43 (0.38, 0.49) P<.001 
Adjusted odds ratios (aORs) of one-year acute rejection loss and length of stay >2 weeks 
(relative to 2003-2006) in older were estimated using logistic regression. Adjusted hazard ratios 
(aHRs) of mortality and graft loss (relative to 2003-2006) in older recipients were estimated using 
Cox models. aHRs and aORs were adjusted for recipient factors (sex, age, race, body mass index 
(BMI), primary diagnosis, life support, hepatocellular carcinoma (HCC), non-HCC malignancy, 
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hepatitis C virus 69, HIV status, diabetic, primary insurance, portal vein thrombosis, and split 
LT), and donor factors (age, race, BMI, HCV, donation after cardiac death (DCD), ABO 
compatibility, as well as donor and recipient geography).  
*The two latest time periods were split at 6/18/2103 after the allocation policy implementation 









Figure 1. Trends in 8,627 older liver transplant (LT) recipients according to year of transplant. (a) 
The number of older LT recipients is shown as a bar (left y-axis), and the percentage of total 
older LT recipients among 58,598 adult LT recipients is shown as a line (right y-axis). (b) For all 
older LT recipients from 2003-2016, the nested cumulative distribution of age at the time of LT 









Figure 2. Cumulative incidence of (a) all-cause graft loss and (b) mortality in older LT recipients 
by year. The year and number of LT recipients is seen to the right of the curve. The most recent 
time periods were split at 6/18/2013 after the allocation policy implementation of Share35. This 
policy increases regional liver allograft offers to patients with MELD score ≥35 to direct 
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Objective: To determine if the association of frailty and waitlist mortality varies by candidate 
age. 
Background: Frailty, a construct developed in geriatrics, is a state of decreased physiologic 
reserve, and is associated with mortality while awaiting liver transplantation (LT). However, older 
candidates have high comorbidity burden and less physiologic reserve, so the relationship 
between frailty and waitlist mortality may vary by candidate age.   
Methods: We studied adults listed for LT at two transplant centers. The Liver Frailty Index 
(LFI; grip strength, chair stands, balance) was measured at evaluation, with frailty defined as 
LFI4.5. We compared the prevalence of frailty in older (65y) and younger (18-64y) candidates. 
We studied the association between frailty, age, interaction between the two, and waitlist 
mortality using competing risks regression adjusted for sex, BMI, and MELD.  
Results: Among 882 LT candidates, 16.6% were 65y. Older candidates were more likely to be 
frail (33.3% vs. 21.7%, p=0.002). Older age (adjusted subhazard ratio [aSHR]: 2.16, 95%CI: 1.51-
3.09, p<0.001) and frailty (aSHR: 1.92, 95%CI: 1.38-2.67, p<0.001) were independently 
associated with higher risk of waitlist mortality. However, the association between waitlist 
mortality and frailty did not vary by candidate age (aSHR of frailty for younger patients:1.90, 
95%CI: 1.28-2.80, p=0.001; aSHR of frailty for older patients: 1.98, 95%CI: 1.07-3.67, p=0.03; 
p-interaction=0.9).  
Conclusions: Older candidates experienced higher rates of frailty than younger candidates. 
However, regardless of age, frailty was associated with nearly two-fold increased risk of waitlist 
mortality. Our data support the applicability of the frailty concept to the whole LT population 







Frailty, a measure of physiologic reserve and increased vulnerability to stressors, was initially 
described by gerontologists in older community dwelling adults.51 Frailty was subsequently 
examined in older general surgery patients,52 kidney transplant candidates and recipients,41,49,53-59 
and recently in liver transplant candidates and recipients, 44,60-64 where it was found to be 
associated with adverse outcomes in these populations. The Liver Frailty Index (LFI), comprised 
solely of performance-based measures (grip strength, balance testing, and chair stands), was 
developed in patients with cirrhosis evaluated for transplantation, and predictive validity was 
assessed with calculation of waitlist mortality.44,60 The LFI improves risk prediction for waitlist 
mortality over the Model for End-stage Liver Disease (MELD) (c-statistic: 0.80 vs. 0.76). Up to 
25% of liver transplant candidates are frail;44,60 beyond waitlist mortality,44 frailty is associated 
with increased hospitalizations64 and depression61 in liver transplant candidates and longer length 
of stay and hospitalized days in liver transplant recipients.62  
 
While there is a higher prevalence of frailty in older adults, there is also a greater burden of 
comorbidities41-43 and an increased prevalence of functional impairment in older adults.42 Older 
candidates may therefore, because of comorbidity burden and underlying functional impairment, 
have a different association between frailty and waitlist mortality as compared to younger 
candidates. Yet, studies of frailty in liver transplant candidates have not examined whether there 
is effect modification by candidate age on the association between frailty and waitlist mortality: 
in other words, whether frailty has the same impact on younger patients as it does on older 
patients.44,60 As the average age of waitlisted liver candidates and liver transplant recipients 




To clarify and quantify the interaction of candidate age and frailty on mortality on the liver 
transplant waitlist, we sought to quantify the prevalence of frailty, compare individual elements 
of the LFI score, and quantify the association of frailty and waitlist mortality, in older and 




Study population  
This was a prospective, longitudinal cohort study of 882 participants, aged 18 years or older, who 
were being evaluated in the outpatient setting for liver transplant at University of California San 
Francisco (n=759) from March 2012 to April 2018 or Johns Hopkins Hospital (n=123) from 
August 2016 to May 2018. We excluded participants with hepatocellular carcinoma (n=500) 
because their waitlist mortality was expected to differ substantially from participants with other 
causes of liver failure. Participants with severe hepatic encephalopathy (n=20), as defined by the 
time to complete the Numbers Connection Test >120 seconds were excluded.42,44 We defined 
older candidates as aged≥65, a commonly used age cut-off.42,66,79 The University of California 
San Francisco Institutional Review Board and Johns Hopkins Institutional Review Board 
approved the study. 
 
Data collection 
We measured the LFI as described below. Additional participant characteristics were abstracted 
from the electronic medical record (age, sex, race, indication for liver transplant, body mass 
index [BMI], MELD score, diabetes, hypertension, coronary artery disease, history of stroke, 
ascites [none, mild/moderate, refractory], and hepatic encephalopathy). Hepatic encephalopathy 
was defined as time >60 seconds to complete the Numbers Connection Test as previously used 
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in liver candidate cohorts.42,44 Physicians were not aware of the measured frailty scores at liver 
transplant evaluation.  
 
Frailty 
We studied the LFI as previously defined in liver transplant candidates.60,62 The LFI is composed 
of three components that include grip strength, balance testing, and chair stands. These objective 
measures were recorded at the time of clinic liver transplant evaluation using the following:  
1. Grip strength: average of three trials in the subject’s dominant hand using a hand 
dynamometer, measured in kilograms  
2. Chair stands: measured as the number of seconds it takes to stand from seated in a 
chair five times with the subject’s arms folded across the chest  
3. Balance testing: measured as the number of seconds that a subject can balance in 
three positions (feet side-to-side, semi-tandem, and tandem) for a maximum of ten 
seconds each 
The LFI was calculated (www.liverfrailtyindex.ucsf.edu):  
(-0.330 x gender-adjusted grip strength) + (-2.529 x number of chair stands per second) 
+ (-0.040 x balance time) + 6 
Standard cutoffs were used to define robust (LFI<3.2), prefrail (3.2 to <4.5), and frail 
(LFI4.5).60  
 
Waitlist mortality  
Among liver transplant candidates, the risk of waitlist mortality was estimated at 6 months, 1 
year, and 3 years using a competing risk framework by candidate age (older [age65] vs. younger 
[age18-64]) and frailty status with transplantation as a competing risk. Also, a competing risk 
framework was used to create unadjusted cumulative incidence curves of waitlist mortality by 
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candidate age and frailty status. The log rank test of equality was used to compare unadjusted 
cumulative incidence curves. Transplantation was considered a competing risk for waitlist 
mortality, and the time origin was date of liver transplant listing. Subhazard ratios of waitlist 
mortality by candidate age were obtained using the Fine and Gray method for competing risks.80 
The final multivariable model was selected for optimal parsimony by minimizing the Akaike 
Information Criteria (AIC) and included adjustment for sex, body mass index 67, and MELD 
score. To test whether waitlist mortality varied by frailty status, an interaction between candidate 
age and frailty was evaluated using a Wald test. Additionally, we quantified the risk of waitlist 
associated with each individual parameter of the LFI and included an interaction between 
candidate age and LFI component.  
 
Statistical analyses  
Comparison of candidate characteristics was performed using chi-squared test for categorical 
variables and t-tests or Wilcoxon rank sum for continuous variables. All analyses were two-tailed 




Baseline characteristics of the entire cohort 
Among the 882 liver transplant candidates, 43.0% were female, 60.1% were Caucasian, and 
16.6% were older (age≥65). The median (interquartile range [IQR]) was 56 (49-60) years for 
younger candidates and 67 (66-68) years for older candidates (p<0.001). The age range of older 
candidates was 65-75 years with 10% of the candidates being age 70 or greater. Older candidates 
were as likely to be Caucasian (69.3% vs. 59.6%), Hispanic (19.1% vs. 24.2%), or African 
American (4.1% vs. 3.8%) (p=0.1) compared to younger candidates. Older candidates had lower 
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MELD scores (median 17 vs. 18, p=0.01) and were more likely to have NASH as the indication 
for liver transplant (26.0% vs. 15.0%, p=0.02), hypertension (55.2% vs. 37.9%, p<0.001), 
diabetes (39.9% vs. 28.3%, p<0.01), and coronary artery disease (12.4% vs. 5.4%, p=0.002). 
Additionally, older candidates were more likely to have hepatic encephalopathy (29.9% vs. 
16.2%, p<0.001) but similarly likely to have ascites (moderate: 31.9% vs. 29.4%, refractory: 5.6 
vs. 7.1%, p=0.7).   
 
Older liver transplant candidates were more likely to be frail (33.3% vs. 21.7%, p=0.002) and 
have higher LFI scores (4.3 vs. 3.9, p<0.001) than younger liver transplant candidates at 
evaluation. 
 
Baseline characteristics by frailty status  
Among the 735 younger liver transplant candidates, frail candidates had a similar average age 
(54.3 years vs. 53.1 years, p=0.2), similar BMI (29.4 vs. 29.2, p=0.9), and were more likely to be 
female (52.3% vs. 40.2%, p=0.01) than nonfrail candidates. Frail candidates were just as likely to 
be Caucasian (63.6% vs. 59.4%), Hispanic (22.0% vs. 23.7%), or African American (2.9% vs. 
4.1%) (p=0.7) compared to nonfrail candidates. Younger frail candidates were more likely to 
have alcoholic cirrhosis (29.9% vs. 24.5%, p=0.001) and NASH (21.7% vs. 13.2%, p=0.001), but 
less likely to have HCV (26.8% vs. 34.6%, p=0.001) and cholestatic disease (7.1% vs. 16.4%, 
p=0.001) as the indication for liver transplant than nonfrail candidates. Also, younger frail 
candidates were more likely to have higher MELD scores (20 vs. 18, p<0.001), diabetes (41.3% 
vs. 24.1%, p<0.001), hepatic encephalopathy (27.5% vs. 13.1%, p<0.001), mild/moderate ascites 
(35.6% vs. 27.7%, p<0.001), and refractory ascites (13.1% vs. 5.3%, p<0.001) than nonfrail 
candidates. Younger frail candidates were just as likely to have history of stroke (1.3% vs. 1.6%, 
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p=0.8), hypertension (40.0% vs. 37.3%, p=0.5), and coronary artery disease (5.0% vs. 5.6%, 
p=0.8) compared to younger nonfrail candidates (Table 1).  
 
Among the 147 older liver transplant candidates, frail candidates had a similar average age (67.1 
years vs. 67.3 years, p=0.6) and similar BMI (30.0 vs. 28.9, p=0.3) compared to nonfrail 
candidates. Older frail candidates were more likely to have alcoholic cirrhosis (32.7% vs. 19.6%) 
and NASH (28.6% vs. 24.7%), but less likely to have HCV (24.5% vs. 33.0%) and cholestatic 
disease (8.2% vs. 11.3%) as the indication for liver transplant than nonfrail candidates. Also, 
older frail candidates had higher average MELD scores (19 vs. 16, p=0.03) and were more likely 
to have mild/moderate ascites (44.7% vs. 25.8%, p=0.03) and refractory ascites (8.5% vs. 4.1%, 
p=0.03) than nonfrail candidates. Older frailer candidates were just as likely to have diabetes 
(40.4% vs. 37.8%, p=0.8), stroke (2.1% vs. 2.0%, p=0.9), hypertension (44.7% vs. 60.2%, 
p=0.1), coronary artery disease (14.9% vs. 11.2%, p=0.5), and hepatic encephalopathy (34.7% vs. 
27.6%, p=0.4) as nonfrail candidates (Table 1).  
 
At the time of liver transplant evaluation, 23.5% of candidates were frail and 16.2% of 
candidates were robust. Older candidates were more likely to be frail (33.3% vs. 21.7%, p=0.002) 
and less likely to be robust (4.8% vs. 18.4%, p<0.001) compared to younger candidates (Figure 
1). Additionally, older candidates had higher LFI scores (average 4.3 vs. 3.9, p<0.001) along with 
poorer median performance for each component of the LFI: male grip strength (30.3 kg vs. 34.0 
kg, p<0.001) and female grip strength (18.9 vs. 20.7, p=0.004), balance testing (30 [25-30] vs. 30 
[30-30] seconds, p<0.001), and chair stands (13.7 vs. 12.2 seconds, p<0.001) compared to 
younger candidates (Table 2).     
 
Waitlist mortality  
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Waitlist mortality was higher in older candidates compared to younger liver transplant candidates 
(log rank p<0.001). The cumulative incidence of waitlist mortality estimated by competing risk 
framework for older versus younger liver transplant candidates was 13.6% (n=20) vs. 7.3% 
(n=54) at 6 months, 23.0% (n=34) vs. 12.6% (n=93) at 1 year, and 42.5% (n=62) vs. 24.9% 
(n=185) at 3 years after listing. After adjustment for candidate sex, BMI, and MELD score, older 
liver transplant candidates had a 2.2-fold higher risk of waitlist mortality (adjusted subhazard 
ration [aSHR]: 2.16, 95%CI: 1.51-3.09, p<0.001) compared to younger liver transplant 
candidates.   
 
Waitlist mortality was higher in frail candidates compared to nonfrail liver transplant candidates 
(log rank p<0.001). The cumulative incidence of waitlist mortality for frail versus nonfrail liver 
transplant candidates was 14.8% (n=31) vs. 6.5% (n=44) at 6 months, 25.2% (n=53) vs. 11.4% 
(n=77) at 1 year, and 46.7% (n=98) vs. 23.1% (n=157) at 3 years after listing. After adjustment 
for candidate age (as continuous variable), sex, BMI, and MELD score, frailty was independently 
associated with a significantly higher risk of waitlist mortality (aSHR: 1.92, 95%CI: 1.38-2.67, 
p<0.001). However, the association between waitlist mortality and frailty did not vary by 
candidate age (p interaction=0.9): Frail older candidates had a higher risk waitlist mortality 
compared to nonfrail older candidates (aSHR: 1.98, 95%CI: 1.07-3.67, p=0.03), as well as frail 
younger candidates compared to nonfrail younger candidates (aSHR: 1.90, 95%CI: 1.28-2.80, 
p=0.001).  
 
Additionally, after assessment of each component of the LFI individually, the risk of waitlist 
mortality decreased by 25% for each 1 unit increase in gender adjusted Z-score for grip strength 
(aSHR: 0.75, 95%CI: 0.64-0.88, p<0.001), and this association did not vary by candidate age 
(interaction p=0.8). The risk of waitlist mortality decreased by 6% for each second increase in 
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balance tests (aSHR: 0.94, 95%CI: 0.92-0.97, p<0.001), and this association did not vary by 
candidate age (interaction p=0.7). There was no association between waitlist mortality and chair 





In this two-center prospective cohort study of frailty in 882 liver transplant candidates, we found 
older candidates were more likely to be frail, less likely to be robust, and had worse performance 
for all components of the LFI (grip strength, balance, chair stands) than younger candidates. 
Additionally, we found frail candidates were two-fold more likely to die on the waitlist. However, 
the impact of frailty did not vary by candidate age.   
 
Less than one in ten older community dwelling adults are frail using the Fried frailty phenotype51 
and the prevalence of frailty increases with age,81 yet nearly one in five liver transplant 
candidates, of all ages, are frail using Fried frailty phenotype.44 Using the Liver Frailty Index, a 
cirrhosis-specific measure of frailty, we found one-third of older liver transplant candidates were 
frail. Our finding that frailty is more common in older liver transplant candidates compared to 
younger liver transplant candidates (33.3% vs. 21.6%, p=0.002) is similar to that seen in kidney 
transplant candidates (age≥65: 23.7% for age≥65 vs. 15.5% for age 18-55), with older kidney 
transplant candidates at a 2.2-fold increased odds of being frail compared to younger kidney 
transplant candidates.58  
 
Not surprisingly, frail candidates are at a higher risk of waitlist mortality, and the quantification 
of this risk with an objective tool such as LFI is critical for identification of patients who are at 
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high risk of waitlist mortality independent of MELD-Na. Importantly, in this large cohort of 147 
older liver transplant candidates, we did not find the association between frailty and waitlist 
mortality to vary by age. This finding expands upon our understanding of the concept of frailty 
in patients with cirrhosis – frailty captures something more than just age-related phenomena 
(e.g., muscle wasting and decreased physiologic reserve that is associated with aging itself), 
although the effects of chronologic aging may make it more likely that an older adult will display 
the frail phenotype. Frailty is a measure of physiologic reserve more than age and MELD-Na 
alone. The effects of cirrhosis that contribute to this manifestation of frailty exert as powerful an 
impact in younger adults with respect to the outcome of waitlist mortality.  
 
Strengths of our study include the fact that this is a large, prospective cohort of frailty at two 
centers with distinctly different patient populations, along with granular ascertainment of 
candidate characteristics and long-term outcome follow-up. One notable limitation of this study 
is the enrollment of only outpatients, and our findings are not necessarily generalizable to 
inpatient liver transplant candidates. However, these are two distinct groups when thinking 
about a prehabilitation intervention prior to liver transplant, and inpatient liver transplant 
candidates would likely not be suitable candidates for a prehabilitation program. Another 
limitation is the use of the LFI is not directly comparable to other more general measures of 
frailty, such as the Fried frailty phenotype. Notably, the LFI includes only performance-based 
measurements, whereas the Fried frailty phenotype is a construct of frailty that likely better 
captures underlying physiologic reserve. 
 
In conclusion, older liver transplant candidates are more likely to be frail by the Liver Frailty 
Index and have lower scores across all components of the LFI. Frailty is associated with waitlist 
mortality, irrespective of candidate age. These findings strengthen with the conceptual 
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framework and biological underpinnings of frailty. Interventions to mitigate frailty in liver 














N 575 160 98 49 
Age, years*  53.1 (9.3) 54.3 (8.2) 67.3 (2.2) 67.1 (1.6) 
Female, %  40.2 52.3 46.9 40.8 
BMI, kg/m2* 29.2 (5.7) 29.4 (6.7) 28.9 (5.4) 30.0 (6.1) 
Race, %     
   Caucasian 57.3 62.5 70.4 67.4 
   Black  4.2 2.5 4.1 4.1 
   Hispanic  24.9 21.9 17.4 22.5 
   Asian  5.4 3.8 3.1 2.0 
   Other  8.3 9.4 5.1 4.1 
Indication for LT, %    
   Alcoholic cirrhosis  24.5 29.9 19.6 32.7 
   NASH  13.2 21.7 24.7 28.6 
   HCV 34.6 26.8 33.0 24.5 
   Cholestatic disease 16.4 7.1 11.3 8.2 
   Other  11.3 14.7 11.3 6.1 
MELD Na* 18.0 (5.4) 19.9 (7.0) 16.2 (5.0) 18.6 (6.8) 
Diabetes, % 24.1 41.3 37.8 40.4 
Stroke, % 1.6 1.3 2.0 2.1 
Hypertension, % 37.3 40.0 60.2 44.7 
CAD, % 5.6 5.0 11.2 14.9 
Hepatic encephalopathy, % 13.1 27.5 27.6 34.7 
Ascites, %      
   None  67.0 51.3 70.1 46.8 
   Mild/moderate 27.7 35.6 25.8 44.7 
   Refractory  5.3 13.1 4.1 8.5 




Table 2. Scores for individual components of the Liver Frailty Index (LFI) by candidate age 
(older: age 65 years and younger: age 18-64 years).  
 
 Younger  Older  p value  
LFI* 3.9 ±0.8 4.3 ±0.8 <0.001 
Grip strength- Male, kg¥ 34.0 (27.7-40.7) 30.3 (25.0-36.7) <0.001 
Grip strength- Female, kg¥ 20.7 (17.0-25.3) 18.9 (15.7-23.3)  0.004 
Balance, sec¥ 30 (30-30) 30 (25-30) <0.001 
Chair stand, sec¥ 12.2 (9.2-16.2) 13.7 (11.2-16.9) <0.001 
*average ± standard deviation 










Figure 2. Cumulative incidence of waitlist mortality by frailty status (liver frailty index 4.5) in 
older (age 65) and younger (age 18-64) candidates. Transplant was treated as a competing risk.   
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Chapter 5. Conclusion 
 
This work examined several challenges regarding use of older liver donors and liver 
transplantation for older recipients. First, the discard of older liver donors and outcomes for 
recipients of older liver donors over time compared to younger counterparts have never been 
previously examined. From our national registry study of 4,427 older liver donor grafts, we 
found that older liver donor graft utilization is declining (6.0% to 3.2%, p=0.001) and older liver 
donor graft discard is increasing (11.6% to 15.4%, p<0.001) since 2003. Discard of older liver 
donors is nearly two-fold higher for every year since 2003 compared to younger liver donors, 
and additionally we found that only 5.7% of older liver donor discard is associated with the 
organ procurement organization level. Among the 3,350 older liver donor recipients from 2003-
2016, we found the risk of all-cause graft loss and mortality decreased by half (all-cause graft loss 
aHR [adjusted hazard ratio]: 0.60, 95%CI: 0.58-0.68, p<0.001, mortality aHR: 0.59, 95%CI: 0.52-
0.68, p<0.001). Further, these improvements in all-cause graft loss and mortality for older liver 
donor recipients are more marked than improvements seen in younger liver donor recipients (all-
cause graft loss p interaction=0.03, mortality p interaction= 0.04). These trends may suggest the 
transplant community has improved the selection of and care for recipients of older liver donors, 
and there may be room for more liberal and broader utilization of older liver donor grafts to 
expand the donor pool. These findings can guide organ procurement organization evaluation of 
potential donors, transplant surgeon utilization of older liver donors, and patient clinical 
decision-making. 
 
Our findings of decreased utilization of older liver donor grafts are important because 
acceptance of older liver donor graft offers provide a survival benefit for candidates over 
remaining on the waitlist and waiting for a younger donor offer that may never come. Our recent 
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work showed that acceptance of an older liver donor graft confers survival benefit (2-fold 
decreased risk of mortality) for waitlist candidates across all MELD scores (MELD 15-40), 
especially in high MELD candidates (MELD 35-40).21 Notably, both older (age≥65) and younger 
(age 18-64) candidates derived a survival benefit from older liver donor graft acceptance.21 
Patients and providers should carefully weigh the consequences of declining an older liver donor 
graft offer, as one-fourth of candidates die on the waitlist without undergoing transplantation 
after such a decline.21 These findings can guide future clinical decision making for transplant 
providers and improve patient counseling in considering offers. Urging for increased utilization 
of older liver donor grafts must be taken into context with donor-recipient matching. Our 
previous work identified, through a full, formal donor-recipient interaction analysis, a preferred 
phenotype of recipients who incurred no additional risk of graft loss or mortality through 
acceptance of an older liver donor graft: recipient age>45, recipient BMI<35, indication for 
transplant other than Hepatitis C, and cold ischemia time <8 hours.73 We recently validated this 
preferred recipient phenotype, showing that, 13 years later, recipients with this phenotype still have 
similar outcomes with livers from older versus younger donors, and that use of older liver donor 
grafts for preferred recipients has increased over time.74 Thus, it seems that the transplant 
community has utilized donor-recipient matching for transplantation of older liver donor grafts, 
which is encouraging. Notably, this thesis work demonstrated that age of older liver donor 
recipients increased over time and the percent of older (age≥65) recipients of older liver donor 
grafts increased over the study period from 2003 to 2016 from 9.3% to 20.2%. 
 
Another key component of future increased utilization of older liver donor grafts will likely need 
to come at the organ procurement organization level. Organ procurement organization 
performance and efficiency are evaluated by the number of procurements performed divided by 
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the number of eligible deaths (donation after brain death donors aged <70 years).16 Thus, donors 
aged 70 and greater are considered ineligible donors, and organ procurement organization 
pursuit of ineligible donors is not specifically tracked. The conversion rates of ineligible donors 
into organ donors have not been quantified. As we urge the transplant community and organ 
procurement organizations to increase the procurement and utilization of potential older liver 
donors, the number of potential older liver donors will need to be quantified as an important 
first step.  
 
From our national registry study of 8,627 older liver transplant recipients, we found that the 
number of liver transplant recipients aged65 increased nearly five-fold from 2003 (N=263) to 
2016 (N=1,144), and older adults accounted for 20.7% of total liver transplant recipients in 
2016. Older liver transplant recipients were more likely to be male, African American, have 
higher a MELD score and portal vein thrombosis in 2013-2016 as compared to 2003-2006. Also, 
recent older recipients were more likely to undergo liver transplantation for hepatitis C virus, 
non-alcoholic steatohepatitis, or hepatocellular carcinoma, and more likely to receive a hepatitis 
C virus positive or donation after cardiac death graft compared to older liver transplant 
recipients in 2003-2006. Despite an increase in the severity of liver disease and number of LTs 
performed in older recipients from 2003 to 2016, there were significant improvements in acute 
rejection (aOR: 0.70, 95%CI:0.56-0.88, p=0.002) and shorter length of stay (aOR: 0.66, 
95%CI:0.57-0.76, p<0.001) along with lower risks of graft loss (aHR: 0.46, 95%CI:0.40-0.52, 
p<0.001) and mortality (aHR: 0.43, 95%CI: 0.38-0.49, p<0.001). These trends can help guide 
appropriate referral for liver transplantation and counseling in older adults with end-stage liver 




As increased age alone should not be a deterrent for liver transplantation candidacy, there are 
common concerns surrounding liver transplantation in older adults. One consequence seen with 
aging is immunosenescence or decline of the immune system and response. This attenuated 
immune response seen in older adults leads to increased susceptibility to infections, cancer, and 
autoimmune diseases,82,83 but also leads to lower rates of acute rejection after transplantation.84 
Age-related changes in the immune system, along with differences in drug absorption, 
metabolism, and excretion, make immunosuppression management for older transplant 
recipients a distinct entity from younger transplant recipients.85 Thus, immunosuppression 
management in older liver transplant recipients is a key component to post-transplant 
management. The ability to find a balance between higher enough immunosuppression levels to 
prevent rejection, but low enough immunosuppression levels to decrease the risk of infections 
and malignancy, which are more common in older transplant recipients, is a difficult task. 
Further research into optimal immunosuppression dosing for older liver transplant recipients is 
necessary. Another concern regarding transplantation of older adults is the higher comorbidity 
burden and functional impairment seen in this population. While pre-transplant clearance for 
comorbidities, such as cardiac, vascular, or renal disease, is a key step prior to listing for liver 
transplantation, these tests may not capture the underlying physical or functional reserve of a 
patient. Additionally, patients without any comorbidity, yet a decreased physiologic or functional 
reserve, may not be identified through standard testing. An adjunct to conventional candidacy 
testing and identification of vulnerable candidates may be through the Liver Frailty Index.   
 
Finally, in our two-center prospective cohort of 882 liver transplant candidates, we found older 
candidates were more likely to be frail (33.3% vs. 21.7%, p=0.002), less likely to be robust (4.8% 
vs. 18.4%, p<0.001), and had worse performance for all components of the Liver Frailty Index 
(grip strength, balance, chair stands) than younger candidates. Additionally, we found frail 
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candidates were two-fold more likely to die on the waitlist (aHR: 2.16, 95%CI: 1.51-3.09, 
p<0.001). However, the impact of frailty did not vary by candidate age (p interaction= 0.9).  
These findings strengthen with the conceptual framework and biological underpinnings of 
frailty. Interventions to mitigate frailty in liver transplant candidates awaiting transplantation 
should be explored.  
 
It should be noted that frailty measured by the Liver Frailty Index in this thesis work includes 
only performance-based measurements (grip strength, balance testing, and chair stands). Thus, 
the data presented are not use of the Liver Frailty Index is not directly comparable to other more 
general measures of frailty, such as the Fried frailty phenotype. Additionally, the Liver Frailty 
Index may not capture the true physiologic reserve of a candidate; however, it does identify 
patients at increased risk of waitlist mortality and other poor outcomes.  
 
These results have spurred a number of future scientific projects including older liver donors and 
older liver transplant recipients. For instance, the identification of specific characteristics of older 
liver donors and recipients will allow us to appropriately transplant these grafts along with 
quantification of survival benefit for older liver donor recipients and subgroup analysis to 
identify recipients who would benefit from transplantation with an older donor versus waiting 
for a younger donor. Donor-recipient matching will allow increased utilization of older liver 
donor grafts in the preferred recipients. Also, the number of potential older liver donors will 
need to be quantified as an important step to increase utilization, and this will take buy in from 
the organ procurement organizations and the transplant community. With increased utilization 
of older liver donors, more candidates will be able to undergo liver transplantation, and the hope 
is that there will be a reduction in waitlist mortality. The improvements in mortality, graft loss, 
rejection, and length of stay for older liver transplant recipients are encouraging. As older 
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candidates become a larger portion of the liver transplant waitlist, we will need to look into 
survival benefit of transplantation with certain donor characteristics (high BMI donors, older 
donors, donation after cardiac death donors) to ensure appropriate donor-recipient matching in 
these candidates and that they derive a survival benefit undergoing transplantation. With the 
prospective frailty cohort focused on functional testing, we will be able to start prehabilitation 
interventions to potentially improve a candidate’s functional status while awaiting 
transplantation. Also, we will be able to quantify the association between frailty, as measured by 
the Liver Frailty Index, and outcomes such as graft loss, mortality, readmissions, and quality of 
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